Neoplasm, Residual
16 treatments and conditions followed through the public trial records. Not medical advice.How a status is set
Lists this condition and the narrower ones beneath it. A condition is not a diagnosis.
Treatments and conditions
| Treatment and condition | Where it stands | Trials |
|---|---|---|
| Blinatumomab for neoplasm, residual | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 3 |
| BLINATUMOMAB + Venetoclax for neoplasm, residual | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Circulating tumor DNA (ctDNA) testing + Datopotamab Deruxtecan for neoplasm, residual | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| ELI-002 2P for neoplasm, residual | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Folfoxiri for neoplasm, residual | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| INCA33890 for neoplasm, residual | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| LENALIDOMIDE + Acalabrutinib + OBINUTUZUMAB for neoplasm, residual | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Low-Dose Radiation Therapy (LDRT) for neoplasm, residual | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| mFOLFOXIRI for neoplasm, residual | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Osimertinib for neoplasm, residual | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| RITUXIMAB + LENALIDOMIDE + Acalabrutinib for neoplasm, residual | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Sugemalimab for neoplasm, residual | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| TAGRAXOFUSP + Azacitidine + Venetoclax for neoplasm, residual | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Tisagenlecleucel for neoplasm, residual | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Tki + blinatumomab for neoplasm, residual | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Zymosan + α-lactalbumin vaccine for neoplasm, residual | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |